Adventist promotes CFO/COO Terry Shaw to president/CEO

Terry Shaw will be Adventist Health System’s president and CEO effective immediately, the company announced Dec. 8.

Shaw has spent 34 years at Adventist, beginning as a business intern in 1982. His resume includes a stint as director of Florida Hospital. He’s been an executive vice president since 1996, CFO since 2000, and COO since 2010.

“It is a tremendous honor and responsibility to be chosen to lead this organization," Shaw said in a press release. "I look forward to building on the successful foundation that has been laid and working with our leaders and employees across the system as we continue our sacred mission of Extending the Healing Ministry of Christ.”

Shaw will oversee Adventist’s 46 hospitals across 10 states, which reported $8.9 billion in operating revenue for 2015 and has about $2.8 billion in net assets.

He’ll be taking over from Don Jernigan, who will be transitioning to a teaching role at the Adventist Health System Leadership Institute after a decade as president and CEO.

“Terry's experience serving as CFO and COO combined with his breadth of organizational understanding from financial, operations and clinical improvement perspectives will serve Adventist Health System well,” Jernigan said. “The future is bright for our organization, and with God's guidance and blessings, AHS will be able to provide even more Christian health care in the communities we serve as a clinically effective, fully integrated health system.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.